Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer

Author(s):
Blok, E.J.; Kroep, J.R.; Kranenbarg, E.M.K.; Duijm-de Carpentier, M.; Putter, H.; Liefers, G.J.; Nortier, J.W.R.; Rutgers, E.J.T.; Seynaeve, C.M.; Velde, C.J.H. van de; IDEAL Study Grp
Published
2018
Publication type
Article / Letter to editor
LetrozoleExtendedAdjuvantSubgroupPostmenopausalIDEAL
Date issued
2018-04-30
Language
English
Is part of
Breast Cancer Research and Treatment (2018), Vol. 168, no. 2, p. 413-420
hdl
1887/75206
doi
10.1007/s10549-017-4601-1